MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Free Report) was the recipient of a significant growth in short interest during the month of September. As of September 15th, there was short interest totalling 62,000 shares, a growth of 22.5% from the August 31st total of 50,600 shares. Approximately 0.6% of the company’s stock are sold short. Based on an average daily volume of 52,600 shares, the short-interest ratio is currently 1.2 days.
MiNK Therapeutics Stock Performance
INKT remained flat at $0.75 during trading on Monday. 15,750 shares of the company’s stock traded hands, compared to its average volume of 97,730. The stock has a market cap of $26.05 million, a price-to-earnings ratio of -1.25 and a beta of 0.06. MiNK Therapeutics has a fifty-two week low of $0.71 and a fifty-two week high of $1.90. The stock has a 50 day moving average price of $0.82 and a 200 day moving average price of $0.91.
MiNK Therapeutics (NASDAQ:INKT – Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.03. Analysts expect that MiNK Therapeutics will post -0.33 earnings per share for the current fiscal year.
Institutional Trading of MiNK Therapeutics
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $9.00 target price on shares of MiNK Therapeutics in a report on Tuesday, August 13th.
Get Our Latest Stock Report on MiNK Therapeutics
About MiNK Therapeutics
MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.
Featured Stories
- Five stocks we like better than MiNK Therapeutics
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- Find and Profitably Trade Stocks at 52-Week Lows
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- What Does Downgrade Mean in Investing?
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.